INO-5150 Triggers Immune Responses, Delays Progression of Prostate Cancer That Returns, Trial Shows

INO-5150 Triggers Immune Responses, Delays Progression of Prostate Cancer That Returns, Trial Shows
The immunotherapy INO-5150 has shown promise as a treatment for prostate cancer that returns after surgery, according to a Phase 1b clinical trial. Inovio Pharmaceuticals’ cancer vaccine generated immune responses in 60 percent of patients with recurrent prostate cancer and delayed the progression of the disease, researchers said. The company presented the findings at the European Society for

Knowledge is power when living with prostate cancer.

Get access to the web’s leading Prostate Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *